← Back to blog

Phosphatidylserine and Memory: What the Clinical Evidence Shows

November 9, 2026
Phosphatidylserine and Memory: What the Clinical Evidence Shows

Phosphatidylserine (PS) has the most memory research of any phospholipid supplement, and the pooled results point to a small, statistically significant benefit on cognitive tests. A 2022 meta-analysis of randomized trials and pre-post studies found a standardized mean difference of 0.22 against placebo. Individual trials disagree, though, and the answer depends on who took it, which PS they took and for how long. Below we go through the trials one by one, so you can see where the signal is and what it does and does not tell you.

Nutrasmarts
nutrasmarts.com
Explore the Evidence Behind Supplements
NutraSmarts links supplement ingredients to peer-reviewed studies and clinical trial citations, helping you examine the research behind phosphatidylserine.
Explore the research

TL;DR

  • A 2022 meta-analysis pooling 5 randomized trials and 4 pre-post studies found a small, significant cognitive benefit of PS over placebo (SMD 0.22).
  • Trials used 100 to 300 mg a day, most at 300 mg, for 6 weeks to 6 months. Results differ by PS source (bovine, soy, marine) and by participant.
  • The strongest signals come from older adults with memory complaints. Evidence in healthy younger people is thinner.
  • The FDA allows only qualified health claims for PS and cognition, and its required wording says the evidence is limited and preliminary.
  • Side effects in trials were mostly mild, with gastrointestinal complaints the most common.

Table of Contents

What the pooled evidence says

The most useful single number comes from the 2022 meta-analysis summarized by the Alzheimer's Drug Discovery Foundation (ADDF). It combined 5 randomized controlled trials (783 participants) and 4 pre-post studies (178 participants). PS beat placebo on cognitive function with a standardized mean difference of 0.22 (95% CI 0.06 to 0.38, p<0.01). Doses ranged from 100 to 300 mg a day, most used 300 mg, and durations ran from 6 weeks to 6 months.

Pooled phosphatidylserine trial results and effect estimate

How big is 0.22? In behavioral research, effects around 0.2 are conventionally called small. The confidence interval stays above zero, so the effect is unlikely to be chance. The ADDF also notes that the trials in the analysis are hard to compare directly, and that small trials suggest slight cognitive improvements that were not large enough to be clinically relevant. Read it as a real but modest signal, and as the reason the research is still active.

The ADDF also explains the biology that makes PS a reasonable candidate. PS is a phospholipid in cell membranes, and its levels and location in the brain can influence signaling pathways involved in cell survival and communication. Brain PS stays mostly constant through life, and it is not yet clear whether supplements raise brain levels. That is an open mechanistic question, not a verdict on the trials.

The key trials, one by one

Pooled numbers hide a lot. These are the studies that shape the picture.

Bovine-cortex PS: the early positive trial

Crook and colleagues (1991) treated 149 patients with age-associated memory impairment for 12 weeks, using 100 mg of bovine-cortex PS three times daily or placebo. The PS group improved on learning and memory tests. The response was greatest in people who performed worst at the start.

Soy PS: a null result and some positive pilots

Jorissen and colleagues (2001) randomized 120 people over 57 with age-associated memory impairment to placebo, 300 mg or 600 mg of soy-derived PS for 12 weeks. No significant differences appeared on any outcome, and the authors concluded soy PS did not affect memory in this group.

A later open-label pilot gave 30 older volunteers with memory complaints 300 mg of soybean-derived PS daily for 12 weeks. Among the 26 who finished (mean age 74.6), recognition, recall, executive function and mental flexibility improved significantly, and blood pressure fell. No serious adverse events were judged treatment-related. With no placebo group, an open-label design cannot separate the supplement from expectation or practice effects.

PS combined with omega-3 (PS-DHA)

In a double-blind, placebo-controlled trial, 157 people without dementia but with memory complaints received PS-DHA or placebo for 15 weeks. Verbal immediate recall improved significantly with PS-DHA, and more people responded. A post-hoc analysis found participants with higher baseline cognitive status were most likely to respond.

A small pilot of 8 older volunteers gave 300 mg PS-omega-3 (marine-sourced, with 37.5 mg EPA+DHA) daily for 6 weeks. Delayed word recall rose 42% (p=0.041). The study had no control group and made no correction for multiple testing, so treat it as hypothesis-generating.

Healthy adults and combination products

Doma and colleagues (2023) ran a randomized, double-blind, placebo-controlled study in 138 healthy adults aged 40 to 65 with self-reported memory problems. Over 42 days, a product combining 100 mg whole coffee cherry extract and 100 mg PS produced greater gains in numeric working memory accuracy and reaction time than placebo. Because the product combined two ingredients, the result cannot be credited to PS alone. A 2025 review of a sunflower-derived PS supplement in healthy adults raised the same point: the combination enhanced memory and cognition, but the effect of PS by itself was not isolated.

At a glance

StudyParticipantsPS form and doseDurationMain finding
Crook 1991149, age-associated memory impairmentBovine cortex, 300 mg/day12 weeksImproved learning and memory, most in lower performers
Jorissen 2001120, age 57+Soy, 300 or 600 mg/day12 weeksNo significant differences
PS-DHA trial157, memory complaintsPS-DHA, 300 mg/day15 weeksBetter verbal immediate recall
Richter 20108, memory complaintsMarine PS-omega-3, 300 mg/day6 weeks42% delayed recall gain, no control group
Open-label pilot30, memory complaintsSoy, 300 mg/day12 weeksImproved memory and executive function
Doma 2023138, healthy 40 to 65100 mg PS plus coffee cherry extract42 daysBetter working memory vs. placebo

Why results differ between studies

Three things explain most of the disagreement.

Source and fatty acids. The ADDF reports that PS fatty-acid composition differs by plant, fish or cow origin, which complicates comparison. Soy PS at 300 or 600 mg a day showed no effect over 12 weeks in one study, while marine PS-DHA improved some, but not most, aspects of cognition. Whether the difference is the PS, the DHA attached to it or the trial design is not settled.

Who was studied. Crook found the biggest response in people with lower baseline performance. The PS-DHA trial found the opposite: people with higher baseline cognition responded most. Those two findings cannot both describe a universal rule, which is why we advise against a blanket expectation of benefit.

Length and design. Most trials ran under 6 months, so long-term use is not well studied. The ADDF also points out that PS composition has varied widely between trials, making direct comparison difficult.

If you are supporting an older relative with memory concerns, supplements are one piece of a bigger picture. Daily routines and caregiving matter just as much, and guidance on evidence-based home care for seniors covers that side.

Does it prevent or treat dementia?

The memory studies above do not establish that PS prevents or treats dementia. In 2003 the FDA authorized qualified health claims that PS may reduce the risk of cognitive dysfunction or dementia in the elderly. The required disclaimers say the research is very limited and preliminary, and that the FDA finds very little scientific evidence for the cognitive-dysfunction claim and little for the dementia claim.

In Alzheimer's disease specifically, a 2-month randomized, placebo-controlled trial gave patients 300 mg PS plus 240 mg phosphatidic acid daily. Stability was 90.6% versus 79.5% on placebo (p=0.066), and the difference in a daily-living score was significant (p=0.021). The ADDF summarizes the wider picture: small trials suggest slight cognitive gains, but effects were short-lived or seen only in severely impaired patients, and larger trials have not confirmed them.

If you or a family member has been diagnosed with Alzheimer's disease or another dementia, talk with the treating physician or neurologist before adding any supplement, so it fits with current medications and care.

Does it prevent or treat dementia?

Doses, duration and safety in trials

The tested range is 100 to 300 mg a day, with 300 mg the most common, taken for 6 weeks to 6 months. These are the amounts studied, not a personal recommendation. Our phosphatidylserine ingredient page lays out dosage benchmarks next to the evidence rating.

Safety data from the same trials:

  • In the 157-person PS-DHA study at 300 mg a day, no significant between-group differences appeared in the safety parameters tested. In the open-label phase, people on PS-DHA for 30 weeks had a 3.1 mmHg drop in resting diastolic blood pressure and a 0.61 kg weight gain.
  • The ADDF reports the same trial had no clinically meaningful lab or physical exam differences and no serious adverse events. It recorded 16 adverse events in 10 PS-DHA participants versus 11 in 8 placebo participants, including 13 gastrointestinal events versus 2.
  • Across a 2022 meta-analysis of nine trials, withdrawals were linked to dizziness, severe psychomotor agitation, itching and gastrointestinal discomfort such as nausea, flatulence and vomiting. It could not be determined whether the intervention caused them, and there were no major adverse events. The ADDF describes PS as thought to be well tolerated, though its safety profile is not thoroughly characterized.

In practice, safe use means starting with the labeled amount, noticing stomach upset, and checking with a pharmacist or doctor if you take blood pressure medication, blood thinners or other prescriptions. The blood pressure changes seen in two studies are a good reason to mention it.

How to choose a phosphatidylserine product well

The trials give you a checklist.

  1. Match the source to the evidence you care about. Trials used bovine cortex, soy and marine PS, and results differed. Our pages on BioPS® (soy), Sharp-PS® (soy-free sunflower) and SerinAid® show the branded forms and what is studied for each.
  2. Look at the dose per serving. Most trial arms used 300 mg a day. Check the Supplement Facts panel for the actual PS amount, not just the blend total.
  3. Notice added ingredients. Several positive trials tested PS with DHA or coffee cherry extract. Those results belong to the combination.
  4. Plan for a trial period. Studies ran 6 weeks to 6 months, so judge results over a comparable window rather than days.
  5. Compare alternatives side by side. If you are weighing PS against another phospholipid, see our phosphatidylserine vs. phosphatidylcholine comparison, and for ranked products read our phosphatidylserine supplement roundup.

For the wider context of ingredients studied for cognition, our guide to supplements for healthy brain aging puts PS alongside others, and the ginkgo biloba evidence review is a useful parallel read.

Our perspective

We built NutraSmarts so people can see how strong the evidence is before they decide, and phosphatidylserine is a good example of why that matters.

The honest summary is that PS has a consistent, modest signal in pooled analyses, concentrated in older adults with memory complaints, alongside trials that found nothing. That is not hype and not dismissal. It is what a rated ingredient looks like. Source, dose, fatty-acid makeup and participant profile all changed the outcome, and that is the information a reader needs to choose well.

This is why our ingredient profiles list the trials, the doses used and the PubMed citations side by side, and why our evidence ratings are there to be read, not decorated. When you compare PS forms, look for the dose and design that match the research you care about.

NutraSmarts

Check the evidence for yourself

Every PS profile on NutraSmarts links to the clinical trials behind it, with dosage benchmarks and an evidence rating, free and without sign-up. Start with the ingredient database, or use the symptom search to see which ingredients have been studied for brain fog or memory concerns. If you formulate supplements, our free browser-based Supplement Facts label creator builds FDA-compliant labels without spreadsheets.

Nutrasmarts

If you suspect low nutrient levels are behind memory or focus changes, our deficiency symptom guide is a good next stop, and the deficiency risk by group page covers older adults.

FAQ

Does phosphatidylserine improve memory?

Pooled data from a 2022 meta-analysis show a small, statistically significant improvement in cognitive function versus placebo (SMD 0.22). Individual trials are mixed, with a positive effect in some older adults with memory complaints and no effect in others. Source, dose and participant profile all appear to matter.

How much phosphatidylserine was used in memory studies?

Clinical trials used 100 to 300 mg a day, most often 300 mg, for 6 weeks to 6 months. One trial also tested 600 mg of soy PS and found no significant difference from placebo. Follow the label on the product you choose.

Is soy or marine phosphatidylserine better for memory?

The evidence does not settle it. A 12-week soy PS trial at 300 or 600 mg found no effect, while a marine PS-DHA trial improved some memory measures. Fatty-acid composition differs by source, which makes the trials hard to compare directly.

Is phosphatidylserine safe?

In clinical trials it was generally well tolerated, with gastrointestinal complaints the most common adverse event and no major adverse events reported in the 2022 meta-analysis. Its safety profile is not thoroughly characterized, and long-term use has been little studied. Ask a doctor or pharmacist if you take prescription medicines.

Can phosphatidylserine prevent dementia?

That has not been established. The FDA allows only qualified claims for PS and dementia risk, with disclaimers that the evidence is very limited and preliminary. Larger trials in Alzheimer's disease have not confirmed the small early benefits.

Sources